Start › Rak jajnika › Ohio › Columbus
Badania kliniczne dla Rak jajnika w mieście Columbus, OH
39 badań dla Rak jajnika szuka uczestników w ośrodkach w mieście Columbus i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RekrutacjaFaza 2
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- i 13 więcej
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RekrutacjaFaza 2
- Site 0243 - Mark H Zangmeister Cancer Center, Columbus
- Site 0214-Ohio State University Comprehensive Cancer Center, Hilliard · 10 mi dalej
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RekrutacjaFaza 2
- The Mark H Zangmeister Center /ID# 275106, Columbus
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RekrutacjaBadanie obserwacyjne
- The Ohio State University Comprehensive Cancer Center, Columbus
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
RekrutacjaFaza 1/2
- The Ohio State University Wexner Medical Center, Columbus
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
RekrutacjaFaza 1/2
- The Ohio State University Wexner Medical Center, Columbus
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
RekrutacjaFaza 2
- Research Site, Columbus
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
RekrutacjaFaza 2
- Jamescare Gynecologic Oncology At Mill Run /ID# 277951, Hilliard · 10 mi dalej
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RekrutacjaFaza 3
- The Mark H Zangmeister Center, Columbus
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Hilliard · 10 mi dalej
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RekrutacjaFaza 2
- The Mark H Zangmeister Cancer Center Ohio, Columbus
- The Ohio State University Wexner Medical Center Division of Gynecologic Oncology, Hilliard · 10 mi dalej
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RekrutacjaFaza 3
- Ohio Health Research Institute, Columbus
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
RekrutacjaFaza 1/2
- Ohio State University, Columbus
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
RekrutacjaFaza 2
- The Ohio State University Comprehensive Cancer Center, Hilliard · 10 mi dalej
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
RekrutacjaFaza 3
- Zangmeister Cancer Center, Columbus
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
RekrutacjaFaza 1
- The Ohio State University (OSU) Wexner Medical Center, Columbus
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RekrutacjaFaza 3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054), Columbus
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
RekrutacjaFaza 3
- OhioHealth Research Institute, Columbus
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RekrutacjaFaza 1
- The Ohio State University, Columbus
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RekrutacjaFaza 1/2
- Research Site, Columbus
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
RekrutacjaFaza 2/3
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
RekrutacjaFaza 1
- Ohio State University Wexner Medical Center, Columbus
Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy
RekrutacjaWczesna faza 1
- Ohio State University Comprehensive Cancer Center, Columbus
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
RekrutacjaFaza 1/2
- The Ohio State University, Columbus
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
RekrutacjaFaza 3
- Site 0108, Columbus
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Rekrutacja
- Ohio State University Comprehensive Cancer Center, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- i 8 więcej
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
RekrutacjaFaza 3
- Ohio State University Comprehensive Cancer Center, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- i 8 więcej
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekrutacjaFaza 1/2
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
RekrutacjaFaza 2/3
- Ohio State University Wexner Medical Center, Hilliard · 10 mi dalej
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RekrutacjaFaza 2
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RekrutacjaFaza 2
- Ohio State University, Columbus
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RekrutacjaFaza 1/2
- Stefanie Spielman Comprehensive Breast Center, Columbus
Lead-212 PSV359 Therapy for Patients With Solid Tumors
RekrutacjaFaza 1/2
- Ohio State University, Columbus
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RekrutacjaFaza 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
RekrutacjaFaza 1
- Ohio State University-James Cancer Hospital and Solove Research Institute, Columbus
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
RekrutacjaFaza 1/2
- Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run, Columbus
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RekrutacjaFaza 1/2
- Stefanie Spielman Comprehensive Breast Center, Columbus
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
RekrutacjaFaza 2
- The James Cancer Hospital and Solove Research Institute - Ohio State University, Columbus
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RekrutacjaFaza 1/2
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekrutacjaBadanie obserwacyjne
- Massive Bio SYNERGY-AI site, Columbus
Badania dla Rak jajnika w innych miastach
- Houston, TX89 badań
- New York City, NY69 badań
- Boston, MA61 badań
- Los Angeles, CA50 badań
- Nashville, TN49 badań
- Arlington, VA46 badań
- Philadelphia, PA44 badań
- St. Louis, MO38 badań
- Chicago, IL36 badań
- San Antonio, TX31 badań
- Cleveland, OH30 badań
- Pittsburgh, PA30 badań
Inne badania w mieście Columbus
- Niedrobnokomórkowy rak płuca56 badań
- Rak piersi39 badań
- Nowotwory (wszystkie typy)38 badań
- Rak płuc37 badań
- Ostra białaczka szpikowa35 badań
- Przewlekła białaczka limfocytowa28 badań
- Nowotwór przerzutowy27 badań
- Rak endometrium25 badań
- Rak jelita grubego i odbytnicy24 badań
- Rak prostaty24 badań
- Szpiczak mnogi24 badań
- Czerniak21 badań
Źródło: ClinicalTrials.gov, dane pobrane 5 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.